Italy Wants €1.2 Billion From Novartis And Roche In Lucentis/Avastin Saga
This article was originally published in The Pink Sheet Daily
The Italian government has said it will pursue Roche and Novartis for €1.2 billion it says the Swiss companies owe to its health service for anticompetitive activities involving Avastin and Lucentis.
You may also be interested in...
With EMA deliberating about Avastin, Novartis and Roche have confirmed that they will appeal the €180.5 million fine imposed on them by Italy’s competition authority for anti-competitive behavior.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.